一品红：全资子公司获得草酸艾司西酞普兰滴剂注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Escitalopram Oxalate Drops, which are indicated for the treatment of depression and panic disorder with or without agoraphobia [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Escitalopram Oxalate Drops [1] - The approved product is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 2: Market Insights - According to data from Minet, the sales scale of Escitalopram in urban and county-level public hospitals in China is projected to be approximately 1.88 billion RMB in 2024 [1]